Quality Appraisal of Ambulatory Oral Cephalosporin and Fluoroquinolone Use in the 16 German Federal States from 2014-2019. by Gradl, G et al.
antibiotics
Article
Quality Appraisal of Ambulatory Oral Cephalosporin and
Fluoroquinolone Use in the 16 German Federal States from
2014–2019
Gabriele Gradl 1,* , Johanna Werning 1, Salka Enners 1 , Marita Kieble 1 and Martin Schulz 1,2,3


Citation: Gradl, G.; Werning, J.;
Enners, S.; Kieble, M.; Schulz, M.
Quality Appraisal of Ambulatory
Oral Cephalosporin and
Fluoroquinolone Use in the 16
German Federal States from
2014–2019. Antibiotics 2021, 10, 831.
https://doi.org/10.3390/
antibiotics10070831
Academic Editors: Rabia Hussain,
Jaya Muneswarao and Zaheer
Ud-Din Babar
Received: 14 June 2021
Accepted: 5 July 2021
Published: 8 July 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 German Institute for Drug Use Evaluation (DAPI), 10557 Berlin, Germany; j.werning@dapi.de (J.W.);
s.enners@dapi.de (S.E.); m.kieble@dapi.de (M.K.); m.schulz@fu-berlin.de (M.S.)
2 Department of Medicine, ABDA–Federal Union of German Associations of Pharmacists,
10557 Berlin, Germany
3 Institute of Pharmacy, Freie Universität Berlin, 12169 Berlin, Germany
* Correspondence: g.gradl@dapi.de; Tel.: +49-30-40004-576
Abstract: Background: Despite concerns about causing bacterial resistance and serious side effects,
oral cephalosporins and fluoroquinolones are still frequently prescribed in Germany. We aimed
to test a method for the detection of regional quality differences in the use of oral cephalosporins
and fluoroquinolones and to apply this to the German federal states. Methods: Use of antibiotics
from 2014–2019 was analyzed using dispensing data from community pharmacies claimed to the
statutory health insurance (SHI) funds. Quality of regional antibiotic use in 2019 was assessed by
calculating indicators based on defined daily doses per 1000 SHI-insured persons per day (DID). Oral
cephalosporin and fluoroquinolone use was followed by linear regression analyses. Results: The
method used was suitable to find meaningful quality differences in ambulatory oral cephalosporin
and fluoroquinolone use between the German federal states. In 2019, DID varied from 1.62 in
Brandenburg to 3.17 in Rhineland-Palatinate for cephalosporins and from 0.47 in Brandenburg to
0.89 in Saarland for fluoroquinolones. The city-states Hamburg, Bremen, and Berlin showed highest
quality with the applied indicator set. From 2014–2019, a significant decrease in utilization of oral
cephalosporins was found in all federal states. During 2017–2019, all states showed a significant
decline of fluoroquinolone use.
Keywords: antibiotic utilization; regional differences; quality appraisal; cephalosporins; fluoro-
quinolones; prescription rates
1. Introduction
Overuse and misuse of antibiotics have favored the development of bacterial resis-
tance which is a public health problem worldwide [1]. Promoting the prudent use of
antibiotics will continue to be part of the European Commission’s Medicines Strategy for
Europe [2]. Germany is a country with low antibiotic consumption, compared both to
other nations worldwide and within the European Union [3]. Numerous nationwide and
regional measures have been developed in order to face the threat of microbial resistance
and Germany strives to establish informative monitoring and surveillance systems as
essential tools of the overall concept [4–6]. Guidelines are in place for the treatment of
common infectious diseases which include first and second-line antibiotics [7,8].
Of particular concern is the use of cephalosporins and fluoroquinolones. Broad-
spectrum penicillins, such as amoxicillin belong to antibiotics of first choice for the treat-
ment of respiratory tract infections (RTI), whereas cephalosporins should be avoided
because of their potential of provoking resistance among Gram-negative bacteria, such
as selection of extended-spectrum beta-lactamases and to increase the risk of Clostridium
difficile infections [9,10]. In addition, the serum/tissue concentration, e.g., from orally
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administered cefuroxime, which is required for efficient treatment of many infections is
in dispute [11].
The World Health Organization (WHO) has redefined the term ‘reserve antibiotic’
as a last resort option and the newly defined so-called ‘watch group antibiotics’, among
them fluoroquinolones and second and third generation cephalosporins, as to having
higher resistance potential and to be recommended as first or second choice treatments
only for a limited number of indications [12]. Due to their risk of severe and potentially
irreversible adverse effects, fluoroquinolones are no longer recommended for minor to
moderate infections and for elderly patients [13].
It has been shown that overall use of antibiotics has decreased in Germany from
2010–2018 [14]. Variation in ambulatory antibiotic prescribing between the 16 federal
states in 2003 was substantial, although the reasons for these differences are not fully
understood [14,15].
Compared to other European countries and in contrast to overall use, the use of
cephalosporins and fluoroquinolones was in the middle range during the study pe-
riod. Compared to the countries with lowest consumption, the use of cephalosporins
was 80–100 times higher in Germany than in Denmark, and the use of fluoroquinolones
was 2.3–3.2 times higher than in the United Kingdom. [16–18]. Therefore, the use of
both antibiotic groups should be monitored with particular vigilance. In all German
regions, cephalosporins belong to the antibiotic groups which are most commonly pre-
scribed, although this is not consistent with guidelines for the treatment of common
infections [14,17,19]. According to Schulz et al., prescription rates of antibiotics for pharyn-
gitis/tonsillitis, scarlet fever, pneumonia, otitis media, and urinary tract infections (UTI)
and the proportion of fluoroquinolones for the treatment of common infections were higher
in Germany in 2009 compared to the recommendation by the European Surveillance of
Antimicrobial Consumption (ESAC) [20]. However, the use of fluoroquinolones and of
cephalosporins has decreased from 2010–2018 in nearly all regions across Germany [14,19].
In the context of the increase in antimicrobial resistance, drug-specific quality indi-
cators for ambulatory antibiotic use in Europe have been developed, derived from ESAC
data [21,22]. Twelve of the 22 proposed ESAC-based quality indicators were found to have
face validity and could be used to better describe antibiotic use in ambulatory care and to as-
sess the quality of national antibiotic prescribing patterns [21,22]. Based on these indicators,
total ambulatory systemic antibiotic use and use over time has been analyzed [21,22].
To the best of our knowledge, no assessment of the quality of antibiotic use has
been made for the German regions–that is, the federal states. We, therefore, aimed to
test the method for the detection of regional differences in the use of cephalosporins and
fluoroquinolones and to apply it exemplarily to the 16 federal states of Germany. An
analysis of the use of oral cephalosporins and fluoroquinolones over time complements
the assessment.
2. Results
2.1. Quality Assessment of Oral Antibiotic Use in 2019
Table 1 lists the nine quality indicators for ranking the federal states with respect to
the use of oral antibiotics. Germany consists of 16 partly sovereign federated states, 13 are
territorial states, and three are city-states (see Table 2). The 16 states were grouped into
quartiles and ranked according to their overall use of oral antibiotics in 2019 (Figure 1).
The following applies to all quality indicators: Values in the first quartile have the highest
quality in the evaluation.
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Table 1. Drug-specific quality indicators for oral ambulatory antibiotic use [21,22].
Label Description
J01 DID use of oral antibacterials for systemic use (J01), expressed in DID
J01D DID consumption of oral cephalosporins (J01D), expressed in DID
J01MA DID consumption of oral fluoroquinolones (J01MA), expressed in DID
J01DC % consumption of 2nd generation oral cephalosporins (J01DC), expressed as percentage 1
J01DD % consumption of 3rd generation oral cephalosporins (J01DD), expressed as percentage 1
J01MA % consumption of oral fluoroquinolones (J01MA), expressed as percentage 1
J01 SV seasonal variation of total oral antibiotic consumption (J01) 2
J01D SV seasonal variation of oral cephalosporin consumption (J01D) 2
J01MA SV seasonal variation of oral fluoroquinolone consumption (J01MA) 2
1 Percentage of total use of oral antibacterials for systemic use (J01). 2 Overuse in the winter quarters (October–December and January–
March) compared with the summer quarters (July–September and April–June) of a 1 year period starting in July and ending in June of the
following year, expressed as a percentage: [DDD (winter quarters)/DDD(summer quarters) − 1] × 100.
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Table 2. Characteristics of German federal states, by state type, area, number of persons insured by statutory health insurance (SHI) funds (Source: [23]), physician density (Source: [24])
and density of community pharmacists in 2019.
Federal State
State Type







Number of Physicians per 100,000 Inhabitants in 2019
Number of Pharmacists 2 per








Baden-Wuerttemberg TS 35,748 9,422,699 206.8 64.9 9.9 4.8 3.7 63.8
Bavaria TS 70,542 11,157,806 217.3 70.6 8.9 5.1 3.8 67.7
Berlin CS 891 3,159,945 283.7 71.5 10.5 7.7 5.1 76.3
Brandenburg TS 29,654 2,264,526 188.3 65.4 8.5 5.1 3.8 49.4
Bremen CS 419 599,781 301.1 68.2 14.3 8.2 5.7 55.2
Hamburg CS 755 1,597,846 292.9 72.9 11.7 7.6 4.6 79.4
Hesse TS 21,116 5,431,318 215.2 64.6 8.4 5.1 3.7 71.7
Lower Saxony TS 47,710 7,050,786 202.2 65.2 9.0 5.4 3.9 61.2
Mecklenburg West Pomerania TS 23,295 1,467,844 207.1 72.8 10.5 6.5 4.3 55.6
North Rhine-Westphalia TS 34,112 15,762,659 211.8 62.9 9.3 5.6 4.4 59.0
Rhineland-Palatinate TS 19,858 3,442,438 195.8 66.0 9.3 4.8 4.1 70.0
Saarland TS 2,571 855,115 221.1 66.4 9.4 6.2 4.9 84.9
Saxony TS 18,450 3,760,346 211.6 66.4 11.2 6.3 4.6 49.8
Saxony-Anhalt TS 20,457 2,062,627 196.4 65.1 8.9 5.8 4.6 59.4
Schleswig-Holstein TS 15,810 2,497,277 203.6 69.9 8.9 5.1 3.8 67.9
Thuringia TS 16,202 1,965,431 202.8 69.1 10.4 5.6 4.8 52.6
1 General practitioners and family physicians. 2 Pharmacists in community pharmacies (data provided by the Federal Chamber of Pharmacists/ABDA—Federal Union of German Associations of Pharma-
cists, Berlin).
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2.2. Use of Cephalosporins in 2019
In the states Brandenburg (1.62 DID), Berlin (1.62 DID), Saxony (1.68 DID), Saxony-
Anhalt (1.74 DID), and Thuringia (1.88 DID), the prescription densities of oral cephalosporins
were lower compared to all other states. In contrast, the shares of second generation
cephalosporins in the use of all oral antibiotics were lowest in Berlin (16.1%), Bremen
(17.7%), Saxony-Anhalt (18.2%), Hamburg (18.5%), and North Rhine-Westphalia (18.7%).
The proportion of third generation cephalosporins was lowest in Bremen (1.1%), North
Rhine-Westphalia (1.3%), Saarland (1.5%), Hamburg (1.7%), and Baden-Wuerttemberg (1.7%).
2.3. Use of Fluoroquinolones in 2019
The share of fluoroquinolones was 6.2% of all oral antibiotic use in Germany. The
prescription densities of fluoroquinolones were lowest in Brandenburg (0.47 DID), Berlin
(0.51 DID), Saxony (0.51 DID), Schleswig-Holstein (0.52 DID), and Thuringia (0.55 DID).
The percentages of fluoroquinolones of all oral antibiotics dispensed showed a different
ranking. In Bremen (4.9%), Schleswig-Holstein (5.4%), North Rhine-Westphalia (5.5%),
Hamburg (5.6%), and Berlin (5.8%) the proportion was lowest.
2.4. Assessment of Federal States Based on Quality Indicators
Hamburg ranked first with six out of nine indicator values in the first quartile and
none in the fourth (6/0). Bremen and Berlin ranked second (5/1). Hamburg and Bremen
also scored best in the quality indicators for cephalosporin use, and Schleswig-Holstein for
fluoroquinolone use. Behind Schleswig-Holstein, Hamburg, Bremen and Berlin showed
the same high quality in the use of fluoroquinolones. For Saxony-Anhalt, North Rhine-
Westphalia and Saarland considerable differences concerning quality indicators were found:
In Saxony-Anhalt, the indicator values J01 DID, J01D DID, and J01DC % were in the first
quartile, but J01DD %, J01MA % and J01M SV in the fourth. Conversely, in North Rhine-
Westphalia the indicator values J01DC %, J01DD % and J01MA % were in the first quartile
and J01 DID, J01 SV and J01MA SV in the fourth. In Saarland, the indicator values J01DD %
and J01D SV were in the first quartile and J01 DID, J01D DID, J01MA DID, and J01MA % in
the fourth.
2.5. Changes in the Use of Cephalosporins from 2014–2019
Figure 2 shows monthly cephalosporin DID in Germany and the calculated trend
component. The percentage differences between 2019 and 2014 values (range −13.7–29.2%)
and average monthly changes for the 16 federal states and Germany are listed in Table 3.
In all federal states, the average monthly DID of cephalosporins decreased significantly
(range −0.007–0.018).
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Table 3. Trends for monthly cephalosporin DID during 2014–2019. Abbreviations: DID2014, Average DID in 2014; DID2019,
Average DID in 2019; ∆, percentage difference between 2019 and 2014 values; Avg, average monthly change in DID. In
order to account for the different alpha levels for the individual federal states due to the Bonferroni-Holm method, Avg that
are significantly different from zero are marked with *; R2, coefficient of determination for the applied model.
Federal State DID2014 DID2019 ∆ Avg p-Value R2
Thuringia 2.65 1.88 −29.2% −0.016 <0.001 * 0.49
Saxony 2.31 1.68 −27.3% −0.012 <0.001 * 0.56
Baden-Wuerttemberg 2.82 2.05 −27.2% −0.014 <0.001 * 0.74
Hesse 4.06 3.06 −24.6% −0.018 <0.001 * 0.56
North Rhine-Westphalia 2.97 2.27 −23.4% −0.014 <0.001 * 0.55
Berlin 2.10 1.62 −22.8% −0.009 <0.001 * 0.58
Germany 2.93 2.28 −22.1% −0.013 <0.001 * 0.57
Hamburg 2.60 2.03 −21.9% −0.011 <0.001 * 0.56
Bremen 2.69 2.13 −20.8% −0.010 <0.001 * 0.42
Brandenburg 2.04 1.62 −20.8% −0.008 <0.001 * 0.49
Saxony-Anhalt 2.19 1.74 −20.5% −0.009 <0.001 * 0.32
Bavaria 3.05 2.43 −20.3% −0.012 <0.001 * 0.51
Mecklenburg West Pomerania 2.71 2.17 −19.8% −0.012 <0.001 * 0.39
Rhineland Palatinate 3.83 3.17 −17.2% −0.013 <0.001 * 0.40
Lower Saxony 3.05 2.53 −17.1% −0.012 <0.001 * 0.35
Schleswig-Holstein 2.66 2.29 −13.9% −0.007 <0.001 * 0.38
Saarland 3.17 2.73 −13.7% −0.008 <0.001 * 0.22
2.6. Changes in the Use of Fluoroquinolones from 2014–2019
Figure 3 shows the monthly DID of fluoroquinolones with the trend component run-
ning in two sections. The percentage differences between 2019 and 2014 values, average
monthly changes for the periods 2014–2016 and 2017–2019 for the federal states are listed
in Table 4. In the period 2014–2016, a significant decrease in average monthly fluoro-
quinolone DID was observed only in the federal states Baden-Wuerttemberg (−0.007 DID),
Rhineland Palatinate (−0.005 DID), Hamburg (−0.004 DID), Mecklenburg West Pomerania
(−0.004 DID), Thuringia (−0.003 DID), Bavaria (−0.003 DID), and Schleswig-Holstein
(−0.003 DID). In the period 2017–2019, by contrast, a decline was significant in all regions,
from −0.029 DID in Saarland to −0.012 DID in Brandenburg.
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Table 4. Trends for fluoroquinolone DID during 2014–2019. Abbreviations: DID2014, Average DID in 2014; DID2019, Average
DID in 2019; ∆, percentage difference between 2019 and 2014 values; Avg, average monthly change in DID. In order to
account for the different alpha levels for the individual federal states due to the Bonferroni-Holm method, Avg that are
significantly different from zero are marked with *; R2, coefficient of determination for the applied model.






Mecklenburg West Pomerania 1.286 0.569 −55.8% −0.004 0.002 * −0.016 <0.001 * 0.899
Hesse 1.488 0.661 −55.6% −0.002 0.081 −0.021 <0.001 * 0.895
Rhineland Palatinate 1.735 0.771 −55.6% −0.005 0.001 * −0.021 <0.001 * 0.903
Schleswig-Holstein 1.165 0.521 −55.3% −0.003 <0.001 * −0.015 <0.001 * 0.940
Baden-Wuerttemberg 1.433 0.641 −55.2% −0.007 <0.001 * −0.012 <0.001 * 0.925
Bremen 1.201 0.550 −54.2% 0.000 0.846 −0.019 <0.001 * 0.866
Hamburg 1.203 0.553 −54.1% −0.004 <0.001 * −0.014 <0.001 * 0.958
North Rhine-Westphalia 1.331 0.615 −53.7% −0.001 0.297 −0.020 <0.001 * 0.903
Thuringia 1.170 0.546 −53.4% −0.003 0.002 * −0.014 <0.001 * 0.901
Saarland 1.892 0.888 −53.0% −0.002 0.237 −0.029 <0.001 * 0.885
Germany 1.310 0.616 −53.0% −0.002 0.019 −0.017 <0.001 * 0.918
Berlin 1.058 0.509 −51.9% −0.001 0.345 −0.015 <0.001 * 0.884
Saxony-Anhalt 1.213 0.594 −51.0% 0.001 0.609 −0.020 <0.001 * 0.820
Bavaria 1.329 0.652 −50.9% −0.003 0.001 * −0.016 <0.001 * 0.926
Saxony 1.032 0.514 −50.2% −0.001 0.448 −0.015 <0.001 * 0.891
Brandenburg 0.929 0.474 −49.0% −0.001 0.140 −0.012 <0.001 * 0.882
Lower Saxony 1.242 0.637 −48.7% 0.000 0.669 −0.021 <0.001 * 0.903
3. Discussion
For the first time, we detected both quantitative and qualitative meaningful differences be-
tween the 16 federal states in the ambulatory use of oral cephalosporins and fluoroquinolones.
3.1. Quality of Oral Cephalosporin Use
Our analysis shows that oral cephalosporins were less frequently dispensed in Ger-
many in 2019 than for example in the high-use country Greece (7.3 DID), but more fre-
quently than for example in the United Kingdom (0.02 DID), Netherlands (0.03 DID), or
Denmark (0.03 DID) [18]. There were large differences between the German federal states.
Due to their potential to generate antimicrobial resistance and their low bioavailability oral
cephalosporins are only considered drugs of second choice for RTI including pneumonia in
guidelines [8,25,26]. Nevertheless, in Germany, an increasing preference of prescribing oral
cephalosporins could be observed in the years 1997–2015, especially for RTI [27]. Seasonal
variation of ambulatory antibiotic use of ≥30% was considered high in a study of antibiotic
use in 26 European countries and was presumably related to diagnostic labelling of bacte-
rial RTI such as bronchitis instead of the common cold or influenza [28]. High seasonal
variation in DID may thus suggest that a large proportion of oral cephalosporins were pre-
scribed for RTI, and consequently most likely not according to guideline recommendations
and thus inappropriately, in the respective states.
Our comparison of quality indicators for the use of cephalosporins between the
federal states revealed that the three city-states Bremen, Hamburg, and Berlin performed
better compared to the territorial states. The proportion of second and third generation
cephalosporins had a strong influence on the evaluation. These substances belong to the
watch group antibiotics as defined by the WHO which are only indicated for specific,
limited number of infections and should be prioritized as key targets of stewardship
programs and monitoring [12].
The seasonal variation in the use of cephalosporins also showed considerable differ-
ences between the federal states. Of note, the higher quality in use of oral cephalosporins
in the city-states was not correlated with low use in this substance class, nor with the
overall use of oral antibiotics. The observation of a higher quality of prescription of oral
cephalosporins in urban regions is interesting and deserves further investigation.
According to the Advisory Council on the Assessment of Developments in the Health
System, ensuring the provision of sustainable, efficient and effective ambulatory healthcare
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in sparsely populated, structurally disadvantaged regions is a challenge in Germany,
and especially rural areas may be threatened by a lower number of general practitioners
(GPs) per inhabitants, compared to cities for example [29]. An evaluation of the National
Association of SHI-physicians showed that the density of all physicians (physicians per
100,000 inhabitants) was higher in the city-states (+38%) than in the territorial states in
2019 [24]. The density of specialists such as ear, nose and throat (ENT) specialists (+45%),
urologists (+24%), and pediatricians (+21%) was also considerably higher in the city-states
than in the territorial states [24]. One could assume that there is a correlation between
physician density and the quality of antibiotic prescribing. However, the fact that the
density of GPs did not differ very much between the federal states in 2019 speaks against a
direct connection, as most antibiotics in 2018 were prescribed by GPs [19]. We also did not
see a correlation between the density of pharmacists and quality of antibiotic prescribing in
2019. Although the two city-states of Hamburg and Berlin had a high density of pharmacists
per 100,000 inhabitants (79.4 and 76.3), Saarland had the highest (84.9), where our analysis
has shown that the quality of cephalosporin and fluoroquinolone prescribing was rather
poor. In Brandenburg the density of pharmacists per 100,000 inhabitants was lowest (49.4),
but quality of antibiotic prescribing was in the middle range.
It can be speculated that various other factors play a role, such as the patient’s expecta-
tions or time pressure during the consultation [30,31] A study on influences on the medical
prescription of antibiotics in Germany has shown that indication, diagnosis and guidelines
are important factors, but the doctor–patient relationship and the pharmaceutical industry
also have an influence [32].
Economic considerations, on the other hand, are unlikely to have had any impact on
the change in the quality of antibiotic prescribing for cephalosporins. According to the
Act to Strengthen Competition in Statutory Health Insurance (GKV-WSG) from 2007, the
prescribing behavior of doctors in Germany from an economic point of view is, above all,
controlled by rebate contracts for generic drug products closed between manufacturers
and health insurance funds [33]. In addition, cephalosporins are low-cost drugs. Their
net cost per daily dose hardly changed in the years 2016–2019 (J07D: 2.0–2.1 EUR/DDD)
and their overall share in the total cost of all prescribed medicinal products was marginal
(0.3–0.4%) [34]. The net cost of penicillins, which are often considered as first line therapy,
was in a comparable range during 2016–2019 (J07C: 1.9–2.1 EUR/DDD) [34].
Encouragingly, the trend analysis of oral cephalosporin DID during 2014–2019 showed
a significant reduction in all federal states. This is in line with the observation of Hol-
stiege et al. that the use of cephalosporins has declined in Germany during the period
2010–2018, predominantly due to a reduction in ambulatory prescriptions for pediatric
patients and, potentially, the introduction of pneumococcal vaccination for children in
2006 [14,35]. In the 2019 guideline on antibiotic therapy for ENT infections, the use of
cefuroxime was restricted compared to the 2008 guideline. For example, this agent is no
longer recommended for use in otitis media acuta [24]. Since cefuroxime represents the
most frequently dispensed oral cephalosporin in Germany, this could be another explana-
tion for the observed decline in the dispensing of cephalosporins.
3.2. Quality of Oral Fluoroquinolone Use
Fluoroquinolones are contraindicated in mild to moderate infections in Germany since
April 2019 due to their serious side effects [13]. The guideline on antibiotic therapy for ENT
infections was adapted to this effect in 2019 [26]. Our analysis shows that Germany has
moved further away from the European high-use countries such as Romania (3.1 DID) and
Greece (3.0 DID) in the use of fluoroquinolones in 2019 towards a low-use country such
as Norway (0.3 DID) [18]. We found that the quality of use of this drug class in 2019 was
highest in Schleswig-Holstein, followed by the three city-states Hamburg, Bremen, and
Berlin. An analysis by Schulz et al. showed that in 2009 there were large differences in the
use of fluoroquinolones between the federal states, and that in Schleswig-Holstein the share
of medical practices that fulfilled the indicator of ‘maximum quinolone prescription rate of
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5%’ was highest [20]. Prescription quality for fluoroquinolones appears to have improved
in the federal states during the study period (data not shown), particularly in Mecklenburg
West Pomerania and Baden-Wuerttemberg. There were still substantial differences in use
of oral fluoroquinolones between Schleswig-Holstein and Saarland. As above with the oral
cephalosporins, it can be assumed that several factors influence quality of fluoroquinolone
prescribing. Again, no correlation with the density of GPs or pharmacists could be found
based on 2019 values. Rather, it stands to reason that the prescription prevalence according
to the guidelines as well as the relevant prescription quality has improved at different rates
in the individual federal states. It can be assumed that for fluoroquinolones prescription
quality was influenced by similar factors as for cephalosporins.
In the case of fluoroquinolones as well, economic considerations are unlikely to have
played a role in their prescription. Fluoroquinolones are also low-cost drugs. Net costs
have not changed in the period 2016–2019 (2.6 EUR/DDD) and also account for a very
small share of the total costs of all prescribed medicinal products (0.1–0.2%).
Trend analysis showed a clear change in trend. For the years 2014–2016, we found a
significant decline in seven states, i.e., Baden-Wuerttemberg, Bavaria, Hamburg, Mecklen-
burg West Pomerania, Rhineland Palatinate, Schleswig-Holstein, and Thuringia. In the
period 2017–2019, a significant downward trend was observed in all federal states. Tran
observed a comparable decline in fluoroquinolone prescribing to privately insured patients
in the United States after the US Food and Drug Administration (FDA) removed systemic
quinolones’ indications for acute, uncomplicated UTI, acute sinusitis, and acute exacerba-
tion of chronic obstructive pulmonary disease in May 2016 [36]. These observations may
demonstrate the effectiveness of measures initiated by the risk assessment procedures for
fluoroquinolones such as those by the Federal Institute for Drugs and Medical Devices
(BfArM) and the European Medicines Agency (EMA) in February 2017, as the beginning of
the downward trend in Germany coincided with the start of the risk assessment procedure
in Europe.
Although the decline in use of oral fluoroquinolones during the evaluation period is
encouraging, their SV2019 values as a measure of potential savings in RTI were above the
5% threshold in all federal states [22]. This indicates that there is still potential for an even
more restrictive use of these antibiotics.
3.3. Conclusions and Recommendations towards Measures for Rational Use of Antibiotics
There are meaningful quantitative differences in the ambulatory use of oral cephalosporins
and fluoroquinolones between the German federal states. Utilizing drug-specific indicators
revealed quality differences that could be adequately quantified. The results may be used
as a benchmark and stimulus for quality improvements in different country regions,
exemplified by the German federal states.
It would be worthwhile to examine the factors that have led to the striking quality
difference between the city-states and the territorial states. In their study of differences in
the quality of antibiotic prescriptions in Berlin in 2016, Witte and colleagues described that
the frequency of antibiotic use among children and adolescents differed greatly among
different nationalities. For example, the frequency was higher among children and ado-
lescents with Lebanese, Turkish and German nationality than among those with Asian
and African nationality [37]. In 2007, however, it was already shown that education is
very effective in significantly reducing the unnecessary prescriptions of antibiotics by GPs
for RTI [38].
Our results suggest that the campaigns that have been conducted in Germany in
recent years with the aim of promoting the prescription of antibiotics by physicians ac-
cording to guidelines and informing patients about their correct use have already been
successful. The campaign ‘Antibiotika gezielt einsetzen’(Targeted use of antibiotics) of the
Health Authorities in Hamburg or the state wide campaign by health insurers, chambers
of physicians/pharmacists, associations and the Ministry of Health ‘Rationale Antibi-
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otikaversorgung in NRW’(Rational antibiotics supply in North Rhine-Westphalia) are
examples [39,40].
We believe that such campaigns are valuable tools to raise awareness of the problem
of antibiotic overuse or misuse. However, their focus is to raise awareness of the issue of
reducing antibiotic use in general. Specific antibiotic groups such as cephalosporins or
fluoroquinolones, where there should be reductions, have not yet been addressed. The
results of our study may help target campaigns in states where the potential for these
savings is highest. Our assessment scheme as well as the conclusions drawn from it can
probably be transferred to other countries or regions.
3.4. Strengths and Limitations
The major strength of this study is that it was based on dispensing data from the
majority of community pharmacies in all federal states of Germany and thus from a highly
representative sample of ambulatory data, representing 88% of Germany’s population.
Only data from privately insured patients were not available. The proportion of privately
insured persons averaged 11% during the analysis period [41]. A further strength is that
the study provides consumption data for both groups of antibacterials, cephalosporins
and fluoroquinolones, at national (higher level of aggregation) and regional (lower level
of aggregation) levels. The use of months as time intervals to assess data over six years is
also a strength. Moreover, the month-by-month analyses, which we conducted, suggested
inappropriate prescribing derived from seasonal variations.
A limitation of our quality assessment is that neither patient data including indica-
tions nor data on disease severity are available in our database. This leaves important
other parameters for the quality of antibiotic prescribing unconsidered, such as the use of
recommended antibiotics for specific indications. Furthermore we cannot exclude that sec-
ond and third line antibiotics have been prescribed to patients previously not responding
to first line antibiotics or for patients at high risk of infection-related complications [42].
The quality indicators represent only relative values and compare the values within Ger-
many. This must be taken into account especially in the case of cephalosporins, for which
use is still high compared to a neighboring country, the Netherlands, where virtually no
cephalosporins are prescribed [17].
4. Materials and Methods
4.1. Study Design
We conducted a longitudinal drug utilization study in the period 2014–2019, querying
the database of the German Institute for Drug Use Evaluation (DAPI) containing anony-
mous dispensing data from community pharmacies claimed to the SHI funds, covering
88% of Germany’s population. All claims data from a representative sample of more than
80% (until June 2019) and more than 95% (from July 2019 onwards) of the community
pharmacies in all 16 federal states were available. Data were extrapolated by regional
factors to 100% of the SHI-insured population [43]. Prescriptions for privately insured
patients are not covered by the database. Data on the indication, treatment duration, or
dosages as well as data on individual patients were not available. Prescriptions from
dentists and other prescriptions that could not be assigned regionally were excluded from
the analyses. The number for SHI-insured persons was obtained from the Federal Ministry
of Health [23]. Physician densities were calculated from data obtained from the National
Association of SHI-physicians [24].
4.2. Measurement of Antibiotic Use
We focused on cephalosporins and fluoroquinolones and looked at ambulatory data
of orally administered drugs since the vast majority of antibiotics are prescribed in the
ambulatory setting [44]. The allocation of the active ingredients was based on the official
version of the German Anatomical Therapeutic Chemical (ATC) classification system with
defined daily doses (DDD) published by the German Institute of Medical Documentation
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and Information (DIMDI) [45]. In general, the DDD is the assumed average daily mainte-
nance dose for the main indication of a drug in adults, but based on information published
by DIMDI, dosages for children have been adjusted. Individual substances were analyzed
according to the ATC code level 5. Antibiotic use was estimated by defined daily doses per
1,000 SHI-insured persons per day (DID) as described previously [17].
4.3. Assessment of the Quality of Antibiotic Drug Use
To compare the quality of oral antibiotic use, we followed the quality indicators pro-
posed by Coenen and Adriaenssens for the comparison of European countries [21,22].
For this purpose, seven of the twelve indicators of the inter-European comparison were
selected and two additional, the share of 2nd generation cephalosporins in all antibiotics,
and the seasonal variation of oral cephalosporin consumption, were added. There were
no claims for 4th generation oral cephalosporins, so the consumption of 3rd generation
oral cephalosporins was equivalent to that of 3rd and 4th generation cephalosporins. Con-
sumption of oral fluoroquinolones (J01MA) was chosen instead of consumption of oral
quinolones (J01M) since during the study period no oral quinolones other than fluoro-
quinolones were dispensed. This set of nine drug-specific quality indicators (see Table 1)
was adapted to assess the use of oral cephalosporins and fluoroquinolones and used to
compare the corresponding quality across federal states in 2019.
4.4. Trend Analysis of Oral Cephalosporin and Fluoroquinolone Use
We evaluated the time course of the use of oral cephalosporins and fluoroquinolones
during the study period. Trend analysis of seasonally adjusted monthly cephalosporin and
fluoroquinolone DID time series were performed. Seasonality within the 12 months was
assumed and determined as a multiplicative seasonal factor. For cephalosporin DID, linear
regression analyses were performed to investigate associations between time as increasing
calendar month and the seasonally adjusted monthly DID (yt) in all federal states. For
these analyses, a linear relationship was assumed between time in month and DID:
yt = β0 + β1 · montht· εt
The average monthly change estimates correspond to the estimated slope β1. The
intercept is indicated by β0 while εt is the error. The errors are assumed to be independent.
Whether the respective trend β1 was significantly different from 0 could be seen from the
p-values of the corresponding t-tests.
For fluoroquinolone DID, segmented regression analyses were performed to inves-
tigate associations between time as increasing calendar month before and after the risk
assessment in February 2017 and the seasonally adjusted monthly DID (yt) in all federal
states. For these analyses, the following linear relationship between time in month and
DID was assumed:
yt = β0 + β1 · montht since 2014 + β2· montht since 2017 · εt
The average monthly change estimates before 2017 correspond to the estimated slope
β1 while the average monthly change estimates since 2017 corresponds to the sum of
estimated slopes β1 + β2. The intercept is indicated by β0 while εt is the error. The errors
are assumed to be independent. Whether the respective trends β1 and β2 were significantly
different from 0 could be seen from the p-values of the corresponding t-tests.
Statistical analyses were conducted using IBM SPSS 22. Statistical tests were performed
at an overall alpha level of 0.05. As each federal state was considered separately, the test
alpha level for each test decision is corrected using the Bonferroni-Holm method to account
for multiple testing. The coefficient of determination R2 was used as a measure of goodness
of fit.
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